Biotrack

Melanoma: Imaging, genetics and immunology

REF: PD 14
Principle investigator:
Susana Puig
Contact details:

susipuig(ELIMINAR)@gmail.com / spuig(ELIMINAR)@clinic.ub.es

Apply

Research framework

The position involves working with a team of scientists studying genetic predisposition to melanoma and skin cancer, the interaction with environmental factors as well as genes involved in development, progression and response to treatment.

The programme is a continuation of work published in J Clin Oncol 2005, Genes Chromosomes and Cancer, Nat Genet 2008, Nat Genet 2009 and J Natl Cancer Inst 2010, Nat Genet 2011, Nature 2011, which has provided furthermore evidences in favour of the role of CDKN2A in melanoma predisposition, the role of MC1R gene and other pigmentation genes as a modifying genes and the evidence that other genes are involved in melanoma susceptibility, nevogenicity and progression. Recently the group also performed expression array studies in keratinocytes and melanocytes according to the genetic status, and also in several conditions (as in the field of cancerization before and after treatment). Several bioinformatics strategies are use to identify genes, loci, GOs or pathways involved in susceptibility, progression, prognosis or response to treatment.

Briefly, our group is a multidisciplinary group working in melanoma from the bed side to the bench. In the past 20 years we have been working mainly in genetic predisposition to melanoma, in genetic alterations in tumours, and their implication in the clinical management of patients. We have published more than 120 papers in international journals and we obtained founding from the NIH, European Community and Spanish Government. We are members of GenoMel, an international collaborative group working in melanoma genetics, BioGenomel, an international consortiu devoted to the study of prognostic genes and IMMOMEC, a FP7 founded consortium working in Merkel carcinoma and immunotherapy.

The purpose of this programme of work will be to apply new genetic technologies in our set of samples, to identify new genes related to melanoma and other skin cancers susceptibility, progression and selection of most convenient treatment (biomarkers and target therapies).

The most common techniques used by the team are: SNP genotyping, massive sequencing, Genome Wide SNP arrays, RNA Expression microarrays, MLPA, quantitative PCR, DNA sequencin, microRNA, Tissue arrays, Immunohistochemistry, Lasser microdisection.

Keywords

Melanoma, skin cancer, genes, susceptibility, prognosis and therapy

Main Challenges

The main challenges we would like to achieve are:

  1. Developement of non-invasive imaging techniques for melanoma diagnosis.
  2. Study of the genetic background in melamnoma susceptibility and photocarcinogenesis.
  3. Development of the study of strategies for the treatment of melanoma and skin cancer: target therapies, immunology and photoprotection.
  4. Aplication of artificial inteligent methods for the evaluation of complex databases of melanoma combining imaging epidemiological, clinical and molecular data.
  5. Development of models in mice of humanized sin for the study of photoprotection and photo carcinogenesis.

It is expected that the selected postdoctoral fellow will be enough independent to do these things between others:

  • Contribute to the design, planning seting up and runing of the experiments, in consultation with the Principal Investigator, in relation to this Project.
  • Record, analyse and write up the results of experiments and ensure that laboratory notebooks are kept fully up to date as a formal record of the research
  • Prepare and present findings of research to the Principal Investigator and other members of the centre.

Team strategic objective in IDIBAPS

Continue working in translational research related to the melanoma. Through imaging, genetics and immunology we will contribute to the study of susceptibility, progression and selection of most suitable treatment for the melanoma. 20 years of previous experience supports it.

(Read eligibility criteria)